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Objective: Recent genome-wide association studies have identified a strong association between obesity and common variants
in the fat mass and obesity associated (FTO) gene. FTO has been detected in the hypothalamus, but little is known about its
regulation in that particular brain structure. The present study addressed the hypothesis that hypothalamic FTO expression is
regulated by nutrients, specifically by glucose, and that its regulation by nutrients is impaired in obesity.
Research design and methods: The effect of intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration of glucose on
hypothalamic Fto mRNA levels was examined in fasted mice. Additionally, the effect of glucose on Fto mRNA levels was also
investigated ex vivo using mouse hypothalamic explants. Lastly, the effect of i.p. glucose injection on hypothalamic Fto
immunoreactivity and food intake was compared between lean wild-type and obese ob/ob mice.
Results: In wild-type mice, fasting reduced both Fto mRNA levels and the number of Fto-immunoreactive cells in the
hypothalamus, whereas i.p. glucose treatment reversed this effect of fasting. Furthermore, i.c.v. glucose treatment also
increased hypothalamic Fto mRNA levels in fasted mice. Incubation of hypothalamic explants at high glucose concentration
increased Fto mRNA levels. In ob/ob mice, both fasting and i.p. glucose treatment failed to alter the number of
Fto-immunoreactive cells in the hypothalamus. Glucose-induced feeding suppression was abolished in ob/ob mice.
Conclusion: Reduction in hypothalamic Fto expression after fasting likely arises at least partly from reduced circulating glucose
levels and/or reduced central action of glucose. Obesity is associated with impairments in glucose-mediated regulation of
hypothalamic Fto expression and anorexia. Hypothalamic Fto-expressing neurons may have a role in the regulation of
metabolism by monitoring metabolic states of the body.
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Introduction
Recent genome-wide association studies have identified a
strong association between obesity and common variants in
the fat mass and obesity-associated (FTO) gene.
1 Individuals
homozygous for the risk allele in diverse ethnic backgrounds
have increased adiposity compared with those devoid of the
risk allele.
2 Despite the association between FTO variants and
obesity, the biological function of FTO and the mechanism
by which FTO variants lead to obesity are not well under-
stood. The majority of studies currently suggest that
increased energy intake, but not reduced energy expendi-
ture, may contribute to the increased adiposity and body
weight in individuals with the FTO risk alleles.
2 Although it
appears that most of FTO variants are located within the first
two introns and exon 2, it remains unclear whether the
obese phenotype in individuals carrying the FTO risk alleles
is due to loss-of-function of FTO or if FTO itself has a role in
the regulation of energy balance. Recent studies using mouse
models with a complete absence of Fto or reduced Fto
expression demonstrated that these mutant mice exhibit
reduced body weight and adiposity compared with wild-type
mice.
3,4 Conversely, systemic overexpression of Fto increases
food intake and body weight in mice, supporting the role for
Fto in the regulation of metabolism.
5
FTO is expressed in various tissues, including the hypotha-
lamus where its levels are especially high.
1,6–8 Hypothalamic
Fto mRNA levels are altered by fasting, and hypothalamic
Fto-expressing cells are activated by feeding.
6–10 Of particular
interest, contrary to the metabolic phenotypes of
Fto-deficient mice and Fto-overexpressing mice, targeted
reduction of Fto expression in the hypothalamic arcuate
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www.nature.com/nutdnucleus (ARC) increased food intake and body weight, while
enhanced Fto expression in ARC produced the opposite
effect.
11 These findings support the hypothesis that Fto
expression is regulated by metabolic states, and that
enhanced hypothalamic Fto expression promotes a negative
energy balance, implicating Fto in the regulation of energy
balance in a tissue-specific manner. However, little is known
about the mechanisms governing the regulation of hypotha-
lamic Fto expression and how specific nutrients may
contribute to fasting-induced and feeding-induced changes
in its expression.
Hypothalamic neurons contribute to the metabolic regu-
lation by altering their own activities or the activities of their
downstream targets in response to hormonal and nutrient
signals. In particular, hypothalamic glucose sensing and
glucose metabolism have a critical role in the regulation of
food intake, energy expenditure, and carbohydrate and lipid
metabolism.
12–17 The importance of hypothalamic glucose
sensing in the regulation of energy homeostasis has been
supported by the findings that hypothalamic responses to
glucose stimulation are attenuated in obesity.
18–21 Therefore,
we hypothesized that hypothalamic Fto expression is
regulated by glucose and this regulation is impaired in
obesity.
Materials and methods
Animals
Male C57BL/6 mice were obtained from Charles River
Laboratories (Montreal, Quebec, Canada). Male wild-type
and ob/ob mice (C57BL/6J background) were obtained from
the Jackson Laboratories (Bar Harbor, ME, USA). Animals
were individually housed under a 12:12 light/dark cycle
(lights on at 0600h) with free access to standard rodent chow
pellets (Prolab RMH 3000, 4.5% fat by weight, Ralston
Purina) except for during fasting and feeding studies. Water
was available throughout the experiment. All studies were
approved by the Institutional Animal Care and Use Com-
mittee (University of Manitoba and Mount Sinai School of
Medicine).
Fasting and intraperitoneal glucose treatment
Mice were fasted for 24, 30 or 48h. Control mice were fed ad
libitum throughout the experiment. Mice were killed by CO2
narcosis followed by decapitation. Trunk blood was collect-
ed, blood glucose level was immediately measured, and
serum was saved and stored at  801C for hormone assays.
The brain was quickly removed and the hypothalamus and
the cerebral cortex were dissected out, immediately frozen
on dry ice and stored at  801C until RNA analysis. Mice
fasted for 30h received a single intraperitoneal (i.p.)
injection of saline or glucose (2mg/g body weight (b.w.)) at
the end of the fasting period. Control mice were fed
ad libitum throughout the experiment and injected i.p. with
saline. Mice were killed 1h after the i.p. injection, and the
blood and tissues were collected as described above. A second
set of mice received the same treatment except that the mice
were perfused as described below 2h after the i.p. injection.
The brain was collected for immunohistochemical analysis.
In a third set of animals, wild-type and ob/ob mice were
assigned randomly to three groups as above (ad libitum fed/
saline-treated, fasted/saline-treated and fasted/glucose-
treated) in each genotype except that the duration of fasting
was 48h in this study. Mice were perfused as described below
2h after the i.p. injection, and the brain was collected for
immunohistochemical analysis.
Fasting and intracerebroventricular glucose injection
Mice were implanted with an intracerebroventricular (i.c.v.)
cannula into the lateral ventricle as described previously.
22
Mice received i.c.v. injection of glucose (100mgi n1 ml) or
saline every 6h during the 30-h fast (five injections in total).
The 100mg dose was chosen because a single i.c.v. injection of
glucose at this dose did not cause significant changes in serum
glucose and insulin levels in mice.
23 Saline was used as a
control vehicle instead of artificial cerebrospinal fluid (aCSF)
because aCSF contains glucose.
22 Mice were killed 1h after the
i.c.v. injection and tissue collection was performed as above.
Ex vivo study
To determine the effect of glucose on hypothalamic Fto
expression, hypothalamic explants from the mouse were
cultured in the presence of low (1mM) or high (10mM)
glucose. Seven ad libitum-fed male C57BL/6 mice were
euthanized by exposing to isoflurane followed by decapita-
tion in the late light cycle (between 1500h and 1530h).
Mediobasal hypothalamus was excised from the brain using
the following landmarks: optic chiasm (rostral), mammillary
bodies (caudal), optic tract (lateral) and apex of the
hypothalamic third ventricle (superior). The excised
hypothalamic tissue was split symmetrically into left and
right halves at the hypothalamic third ventricle. Cerebral
cortex (including cingulate/retrosplenial, motor, somatosen-
sory, retrosplenial agranular and retrosplenial granular
cortex) was also excised and split in half at the midline.
Each half of the tissue from the same animal was immedi-
ately cultured in Dulbecco’s modified Eagle’s medium
containing 1% fetal bovine serum, 1% penicillin/streptomy-
cin and 1 or 10mM glucose at 371C with 5% CO2. Explants
were harvested after a 2-h culture and stored at  801C until
RNA analysis.
Feeding study
Wild-type (þ/þ) and ob/ob mice were adapted to a liquid
diet (F0514SP, BIO-SERV, Frenchtown, NJ, USA). Mice were
fasted for 8h during the light period in the diurnal cycle and
injected i.p. with glucose (2mg/g b.w.), cholecystokinin
(CCK-8, Sigma-Aldrich, St Louis, MO, USA, 10mg/kg b.w.)
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cycle. Ad libitum-fed mice were injected i.p. with 2-deoxy-D-
glucose (2-DG, Sigma-Aldrich, 500mg/kg b.w.) or saline at
1200h. Food intake was measured for a period of 30min
after glucose and CCK-8 treatment, and for 2h after 2-DG
treatment. The doses used in the present study have been
shown to be effective in altering food intake in the mouse
strain used here.
24
RNA analysis
Total RNA was extracted from the tissue of individual animal
and mRNA expression levels were measured by real-time PCR
using specific primers (Supplementary Table 1), as described
previously.
25 Levels of mRNA were normalized to b-actin or
cyclophilin mRNA levels, and are expressed as means (% of
the control group)±standard error of mean (s.e.m.). All
reactions were performed in triplicates and the coefficient of
variation was o5% for each triplicate.
Immunohistochemistry
Mice were deeply anesthetized with i.p. injection of avertin
(8mg/g b.w.) and perfused transcardially with ice-cold
heparinized 0.1mol/l phosphate buffered saline (PBS, pH
7.3) followed by ice-cold 4% (w/v) paraformaldehyde (Sigma-
Aldrich) in 0.2mol/l PBS. Mice were decapitated, the brains
were removed and stored at 41C in 2% (w/v) paraformalde-
hyde for 3h, and then transferred to 0.1mol/l PBS contain-
ing 10% (w/v) sucrose and 0.04% (w/v) sodium azide at 41C
for 16h before sectioning. Transverse sections (30mm) were
cut on a cryostat and preserved as free-floating sections in
cryoprotectant (0.1mol/l PBS, 30% [w/v] sucrose, 1% [w/v]
polyvinylpyrrolidone and 30% [v/v] ethylene glycol) and
stored at  201C until use for immunohistochemistry.
Cryosections were washed in 0.01mol/l PBS for 3h and
permeabilized with 0.01mol/l PBS containing 0.5% (v/v)
Triton-X-100 for 30min at room temperature. Sections were
incubated with a polyclonal rabbit or guinea pig anti-Fto
(1:2500) diluted in 0.1mol/l PBS containing 2% (w/v) bovine
serum albumin overnight at 41C.
3 Sections were then
washed three times for 1h in 0.01mol/l PBS followed by a
2-h incubation with a Cy3-conjugated goat anti-rabbit IgG
(1:200, Jackson ImmunoResearch Laboratories, West Grove,
PA, USA) or a fluorescein isothiocyanate (FITC)-conjugated
donkey anti-guinea pig IgG (1:200, Jackson ImmunoResearch
Laboratories) at room temperature. Sections were then washed
three times for 15min in 0.01mol/l PBS, placed on slides and
mounted using an aqueous antifade mounting medium
containing 40,6-diamidino-2-phenylindole (DAPI; Fluoro Gell
II with DAPI, Electron Microscopy Sciences, Hatfield, PA, USA).
Omission of primary antibody produced no immunoreaction.
Histological quantification
Immunohistochemistry was performed in at least two
sections per animal covering the ventromedial nucleus
(VMN), ARC, the dorsomedial nucleus (DMN) and the lateral
periarcuate area (LPA) of the hypothalamus. Immunofluor-
escent images were viewed using a Zeiss Axioskop2 fluores-
cence microscope with image capture using Axiovision 3.0
software (Carl Zeiss Canada, Toronto, Ontario, Canada). The
same scanning parameters and exposure times were used for
all images taken from sections involving comparisons
between treatment groups. Images were adjusted for contrast
to remove empty pixels by applying the same parameters for
each chromophore (Photoshop Ver. 6.0, Adobe Systems,
San Jose, CA, USA). Numbers of Fto-immunoreactive cells
were counted in the VMN, ARC, DMN and LPA using the
NIH ImageJ software (Ver. 1.43, NIH, Bethesda, MD, USA).
The sum of Fto-positive cells on both sides of the brain was
calculated. The counts in the two sections were averaged in
each animal and used for statistical analysis.
Blood chemistry
Blood glucose levels were measured using a glucose meter
(ELITE XL, Bayer HealthCare, Mishawaka, IN, USA). Serum
concentrations of insulin and leptin were measured by
enzyme-linked immunosorbent assay with commercial kits
from Millipore (St Charles, MO, USA) or Mercodia AB
(Uppsala, Sweden) and R&D Systems Inc. (Minneapolis,
MN, USA), respectively.
Statistical analysis
Means±s.e.m. of all the animals in each group were
calculated. Statistical analyses were performed by one-way
analysis of variance followed by Tukey–Kramer or Dunnett’s
post hoc test. Comparisons between two different treatment
groups were performed by Student’s t-test. Kruskal–Wallis
test was performed and the Bonferroni-corrected Wilcoxon
test was used for post hoc analysis when the data were not
normally distributed. Comparisons between two treatment
groups were performed by Wilcoxon test when the data were
not normally distributed. Correlation analyses were per-
formed between blood glucose levels and Fto expression.
Differences were taken to be significant if Po0.05. Part of
body weight and blood chemistry data (Figures 2a–d) were
reported previously to address a separate hypothesis.
26
Results
Hypothalamic Fto mRNA levels after fasting
Fasting for 24h, 30h and 48h significantly reduced
hypothalamic Fto mRNA levels by 53%, 54% and 50%,
respectively, compared with the ad libitum-fed condition
(Figures 1a and e). Blood glucose, serum insulin and leptin
levels were significantly reduced after the 30-h fast (Figures
1b–d). Fto mRNA levels in the cerebral cortex, measured as a
control only at the 30h fast period, were not affected
(P¼0.19 by Student’s t-test, Figure 1e).
Glucose-induced hypothalamic Fto expression
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glucose
Compared with the ad libitum-fed saline-treated controls in a
second group of mice, body weight and blood levels of
glucose, insulin and leptin were again significantly reduced
in 30-h fasted mice (Figures 2a–d). Glucose treatment (i.p.)
did not cause any significant changes in body weight, serum
insulin and leptin levels in fasted mice (Figures 2a, c and d).
Although there was a trend towards an increase in blood
glucose levels by i.p. glucose injection, the effect did not
reach statistical significance (P¼0.07 by Tukey–Kramer test,
Figure 2b). Blood glucose levels were not significantly
different between saline-treated ad libitum-fed mice and
glucose (i.p.)-treated fasted mice (P¼0.73 by Tukey–Kramer
test, Figure 2b). Fasting significantly reduced the hypotha-
lamic levels of Fto mRNA by 53% compared with saline-
treated ad libitum-fed mice (Figure 2e). Glucose treatment
(i.p) significantly increased Fto mRNA levels by 50%
compared with i.p. saline injection in fasted mice (Figure 2e).
Hypothalamic Fto mRNA expression in fasted mice given i.c.v.
glucose
Compared with the saline-treated control group, i.c.v.
glucose treatment significantly increased the levels in blood
glucose while having no effect on body weight, and serum
insulin and leptin levels (Table 1). The i.c.v. injection of
glucose significantly increased hypothalamic Fto mRNA
levels compared with saline injection (Figure 3). The same
glucose treatment did not cause any significant changes in
Fto mRNA levels in the cortex (P¼0.41 by Wilcoxon test,
Figure 3).
Fto mRNA expression in hypothalamic tissues cultured ex vivo
in the presence of low or high glucose
Exposure of hypothalamic explants to 10mM glucose
significantly increased Fto mRNA levels by 27% compared
with 1mM glucose (Figure 4). Fto mRNA levels in the
cultured cortical explants were not significantly different
between 1 and 10mM glucose (Figure 4).
Hypothalamic Fto-expressing cells after fasting and i.p. glucose
By immunohistochemistry, Fto was found to be expressed
throughout the brain, including the hypothalamic VMN,
ARC, DMN, LPA, paraventricular nucleus and retrochias-
matic area. Quantitative analysis of Fto-positive neurons
counterstained with DAPI showed Fto to be present in 72%,
62% and 72% of the DAPI-stained neurons in the VMN, ARC
(Supplementary Figure 1) and DMN, respectively. Fasting for
30h significantly reduced the number of Fto-immunoreac-
tive cells in VMN, but not in ARC (Figures 5b and c). As in
30-h fasted mice taken for Fto mRNA analysis, blood glucose
levels were significantly reduced in the fasted mice
compared with the ad libitum-fed mice taken for immuno-
histochemical analysis (Figure 5a). The number of
Fto-immunoreactive cells in both VMN and ARC of fasted
mice was significantly increased after i.p. glucose treatment
(Figures 5b and c). Blood glucose levels in fasted mice were
significantly increased 2h after i.p. glucose treatment
compared with saline treatment (Figure 5a). There was a
Figure 1 Fto mRNA expression in the hypothalamus and cerebral cortex
in response to fasting. (a) Hypothalamic Fto mRNA is lower in mice fasted for
24 or 48h vs ad libitum-fed mice (time 0). (b–d) Mice fasted for 30h vs
ad libitum-fed mice exhibit reduced blood levels of glucose, insulin and leptin.
(e) Fto mRNA is reduced in hypothalamus but not cerebral cortex after a 30-h
fast. mRNA expression measured by real-time PCR; values in ad libitum-fed
mice were set to 100%. Data are means±s.e.m. (n¼7–10/group). *Po0.05,
**Po0.01,
#Po0.005,
##Po0.001,
yPo0.0005 compared with ad libitum-fed
group (Dunnett’s test in (a) and Student’s t-test in (b–e)).
Glucose-induced hypothalamic Fto expression
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and the number of VMN Fto-immunoreactive cells
(Figure 5d). A positive correlation between blood glucose
levels and the number of Fto-immunoreactive cells in ARC
did not reach statistical significance (r¼0.4697, P¼0.08).
Hypothalamic Fto expression after fasting and glucose treatment
in obese mice
A 48h fast significantly reduced blood glucose levels, and i.p.
glucose treatment partially reversed this effect both in wild-
type and ob/ob mice (Figure 6g). The 48h fast caused a
significant reduction in the number of Fto-immunoreactive
cells in the VMN and LPA of wild-type mice, as well as in the
ARC, in contrast to the absence of an effect in ARC after a
30-h fast period (Figures 6a, b and h–j). The 48h fast did not
alter the number of Fto-immunoreactive cells in any of these
hypothalamic areas in ob/ob mice (Figures 6d, e and h–j).
Glucose vs saline treatment of fasted wild-type mice
significantly increased the number of Fto-immunoreactive
cells in VMN and ARC by 13.1% and 31.8%, respectively
(Figures 6b, c, h and i). This effect of glucose was absent in
ob/ob mice (Figures 6e, f, h and i). The number of
Fto-immunoreactive cells in LPA was not changed by i.p.
Table 1 Effect of intracerebroventricular injection of glucose on body
weight, concentrations of blood glucose, serum insulin and leptin in fasted
mice
Saline Glucose P
a
Body weight (g) 21.3±0.6 21.6±0.6 0.6864
Blood glucose (mg/dl) 64.3±2.2 88.4±4.2 o0.0001
Serum insulin (ng/ml) 0.18±0.04 0.16±0.03 0.6205
Serum leptin (ng/ml) 0.76±0.19 0.66±0.23 0.7332
aP-values by Student’s t-test or Wilcoxon test. Values are means±s.e.m.
(n¼7–10/group).
Figure 2 Fto mRNA expression in the hypothalamus in response to i.p. glucose treatment in mice. (a–d) Body weight, blood levels of glucose, insulin and leptin are
lower in mice fasted for 30h vs ad libitum-fed mice. This fasting effect is not reversed 1h after i.p. glucose treatment. (e) Fto mRNA is reduced in hypothalamus after a
30-h fast and is increased after i.p. glucose treatment. mRNA expression measured by real-time PCR; values in saline-treated ad libitum-fed mice (fed/saline) were set
to 100%. Data are means±s.e.m. (n¼6–8/group). Groups that do not share a common letter are significantly different (Po0.05, Tukey–Kramer test or Wilcoxon
test with Bonferroni correction).
Glucose-induced hypothalamic Fto expression
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(Figure 6j). Neither fasting nor glucose injection affected
the number of Fto-immunoreactive cells in DMN of wild-
type or ob/ob mice (Supplementary Figure 2).
Figure 3 Fto mRNA expression in the hypothalamus and cerebral cortex in
response to i.c.v. glucose treatment in mice. Fto mRNA is reduced in the
hypothalamus but not in the cerebral cortex after i.c.v. glucose treatment.
Mice were fasted for 30h, injected i.c.v. with saline or glucose every 6h, and
euthanized 1h after the final injection. mRNA expression measured by real-
time PCR; values in saline-treated mice were set to 100%. Data are
means±s.e.m. (n¼9–10/group). *Po0.05 compared with saline-treated
group (Student’s t-test).
Figure 4 Fto mRNA expression in hypothalamic and cortical tissues cultured
in low or high glucose medium. The hypothalamus and cortex were excised
from the mouse brain fed ad libitum and cultured ex vivo for 2h in the
presence of low (1mM) or high (10mM) glucose. mRNA expression measured
by real-time PCR; values in low glucose treatment were set to 100%. Data are
means±s.e.m. (n¼6–7/group). P-values were obtained by Student’s t-test.
Figure 5 Number of Fto-immunoreactive cells in the hypothalamus in
response to i.p. glucose treatment in mice. (a) Blood glucose levels are
reduced by a 30-h fast and increased 2h after i.p. glucose treatment. (b–c)
The number of Fto-immunoreactive cells in VMN is reduced after a 30-h fast
and the number of those cells in VMN and ARC is increased 2h after glucose
treatment. (d) The number of VMN Fto-immunoreactive cells is positively
correlated with blood glucose levels. Fto-immunoreactive cells were visualized
by Immunohistochemistry, and the number of these cells was counted. Data
are means±s.e.m. (n¼5–8/group). Statistical analysis was performed using a
one-way analysis of variance followed by Dunnett’s test (a–c).
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and ob/ob mice
In wild-type mice, i.p. glucose or 2-DG injection significantly
reduced or increased food intake compared with saline
injection, respectively (Figures 7a and b). These effects were
abolished in ob/ob mice (Figures 7a and b). I.p. injection of
CCK-8 significantly reduced food intake both in wild-type
and ob/ob mice (Figure 7c).
Figure 6 Number of Fto-immunoreactive cells in the hypothalamus in response to i.p. glucose treatment in obese mice. (a–f) Representative Fto
immunofluorescent staining of hypothalamus of wild-type (þ/þ, a–c) and ob/ob (d–f) mice fed ad libitum and treated with i.p. saline (a, d), fasted for 48h
and treated with i.p. saline (b, e) or fasted for 48h and treated with i.p. glucose (c, f). (g) Blood glucose levels are reduced by a 48-h fast and increased 2h after i.p.
glucose treatment. (h–j) The number of Fto-immunoreactive cells in VMN, ARC and LPA is reduced after a 48-h fast in wild-type mice, but not in ob/ob mice. Glucose
treatment (i.p.) increases the number of Fto-immunoreactive cells in VMN and ARC in wild-type mice, but not in ob/ob mice. Fto-immunoreactive cells were
visualized by Immunohistochemistry, and the number of these cells was counted. Data are means±s.e.m. (n¼7–10/group). Groups that do not share a common
letter are significantly different within each genotype (Po0.05, Tukey–Kramer test). Scale bar¼500mm. 3v: third ventricle.
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Consistent with reports describing widespread Fto mRNA
expression in the central nervous system, Fto-immunoreactive
cells were found in many areas of the mouse brain,
including various areas in the hypothalamus that are
involved in the regulation of energy balance.
6–9 In these
hypothalamic areas, 60–70% of cells expressed Fto, as
determined by immunolabeling for Fto, with DAPI staining
for identification of cell nuclei. Based on the findings of a
previous report demonstrating that Fto-expressing glial cells
are very rare, Fto-immunoreactive cells detected in the
present study are most likely neuronal cells.
8 Localization
of Fto in the nucleus is consistent with the proposed role of
Fto in the regulation of gene expression as a DNA
demethylase and transcriptional coactivator.
6,27–29 These
Fto expression patterns indicate that Fto has a role in the
regulation of energy balance by altering the activities of
subsets of hypothalamic neurons.
The association between FTO variants and obesity raises
the possibility that Fto has a role in the regulation of
metabolism and that expression of hypothalamic Fto may be
regulated by nutritional signals. Consistent with this idea,
fasting reduces hypothalamic Fto mRNA levels in mice with
one exception in which 16h fast increased hypothalamic Fto
mRNA.
6,7,9,10 We confirmed these findings by demonstrating
that fasting is not only associated with reduced hypotha-
lamic Fto mRNA levels, but also with a reduced number of
Fto-immunoreactive cells in the mouse hypothalamus. The
restriction of fasting-mediated alterations in Fto expression
to specific hypothalamic areas,
6,10 together with the lack of
such alterations in the cerebral cortex, suggests that nutri-
tional effects on Fto may occur within particular nutrient-
sensing neuronal pathways in the hypothalamus. This
further suggests the possibility that Fto may be part of
hypothalamic neuronal pathways that monitor the meta-
bolic status of the body.
In mice, the activity of hypothalamic Fto-expressing
neurons was increased at the end of a meal, suggesting that
these neurons may be responsive to feeding or increased
availability of specific nutrients and hormones.
9 Hypotha-
lamic activity is altered by local glucose availability in the
brain.
23,30 Expression levels of hypothalamic nutrient-sensi-
tive genes are altered by i.p. glucose injection, and this effect
is blocked by i.c.v. injection of 2-DG.
31 Furthermore, changes
in glucose concentration result in alterations in nutrient-
sensitive neuropeptide gene expression in hypothalamic
tissues cultured ex vivo or in immortalized hypothalamic
cell lines.
32–34 In the present study, the reduced number of
Fto-immunoreactive cells observed in the VMN and ARC
after fasting was partially reversed by the elevation of blood
glucose levels following i.p. glucose treatment. There was a
significant positive correlation between blood glucose levels
and the number of Fto-immunoreactive cells in VMN. We
have also demonstrated that i.c.v. glucose administration
increases hypothalamic Fto mRNA levels, and exposure of
the hypothalamic explants to high glucose causes a sig-
nificant increase in Fto mRNA levels. These data support the
hypothesis that an increase in local glucose availability
triggers an induction of Fto mRNA expression specifically in
Figure 7 Feeding response to i.p. injection of glucose, 2-DG and CCK-8 in
obese mice. Glucose-induced anorexia is absent in ob/ob mice (a). CCK-8
reduces food intake in both wild-type (þ/þ)a n dob/ob mice (b). 2-DG
increases food intake in wild-type mice, but not in ob/ob mice (c). Food intake
was measured for 30min (a, b)o r2 h( c) after i.p. injection of glucose or
CCK-8, or 2-DG in mice fasted for 8h (a, b) or fed ad libitum (c). Control mice
received i.p. saline injection. Food intake in saline-treated control group in
each genotype was set to 100%. Data are means±s.e.m. (n¼5–6/group).
Groups that do not share a common letter are significantly different (Po0.05,
Tukey–Kramer test).
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glucose availability in the hypothalamus, at least partly,
mediates the inhibitory effect of fasting on hypothalamic Fto
expression.
Fasting causes a variety of neuroendocrine and metabolic
changes, such as a decline in leptin, insulin and glucose,
and an elevation in glucocorticoids and free fatty acids.
Changes in these nutritional and hormonal signals may
contribute to the fasting-induced reduction in hypothalamic
Fto expression and may also underlie the effects of feeding
on Fto expression. For example, treatment with insulin,
leptin or glucose reverses fasting-induced changes in
hypothalamic nutrient-sensitive gene expression.
35–39
Streptozotocin (STZ) treatment causes diabetes with hyper-
glycemia, hypoinsulinemia and hypoleptinemia in mice
(Supplementary Figures 3a–c). Hypothalamic Fto mRNA
levels were not different between control non-diabetic
and STZ-induced diabetic mice (Supplementary Figure 3d).
These data support the possibility that insulin and leptin also
affect hypothalamic Fto expression. Thus, reduced insulin
and leptin levels may counteract the stimulatory effect of
glucose (hyperglycemia) on Fto expression, resulting in no
alteration in hypothalamic Fto mRNA levels in STZ-induced
diabetic mice. In contrast, in normal mice, we found
that increased hypothalamic Fto mRNA levels after glucose
treatment occurred in the absence of significant changes
in serum insulin levels, suggesting that insulin may not
be a major factor in regulating Fto expression under this
condition.
The fasting-induced reduction and glucose-induced
increase in hypothalamic Fto expression seen in wild-type
mice were absent in ob/ob mice. A recent study also showed
that long-term caloric restriction reduces hypothalamic Fto
protein expression in wild-type mice and this response was
absent in leptin-resistant db/db mice.
40 These observations
raise two possibilities. It may be that the leptin-deficient
ob/ob mice are unresponsive to these metabolic cues due to
either a direct or indirect role of leptin in regulating
hypothalamic Fto expression. Alternatively, the high circu-
lating glucose levels in ob/ob mice may have maximized
hypothalamic Fto expression such that further i.p. glucose
treatment was rendered ineffective. At present, we cannot
distinguish between these two possibilities. It is noteworthy,
however, that in contrast to the lack of an effect of fasting on
hypothalamic Fto protein expression, fasting has been
shown to reduce hypothalamic Fto mRNA in ob/ob mice.
7
Hypothalamic Fto mRNA levels were reported to be reduced
in ob/ob mice compared with those in wild-type mice and
this effect was reversed by leptin treatment.
10 Taken
together, it appears that Fto expression is regulated at the
transcriptional level in both leptin-dependent and leptin-
independent manner, while at the translational levels
hypothalamic Fto expression may be regulated by a leptin-
dependent mechanism. These findings also support the
possibility that leptin as well as glucose participates in the
regulation of hypothalamic Fto expression.
Although we show that glucose increases hypothalamic
Fto expression, the mechanism behind this regulation is
unknown. Leptin increases Fto expression via activation of
the transcription factor cut-like homeobox 1 (CUX1) isoform
P110 that is cleaved from the full-length CUX1 isoform P200
by a protease cathepsin L.
10 Fasting reduces the activity of
cathepsin L and the levels of P110 protein in the hypo-
thalamus, suggesting the possibility that hypothalamic
cathepsin L and CUX1 mediate the effect of metabolic
signals including leptin on hypothalamic Fto expression.
10
Interestingly, similar to the Fto knockout mice, cathepsin L-
deficient mice exhibit the lean phenotype and improved
glucose tolerance.
41 Glucose and insulin affect the protein
expression and activity of cathepsin L in several different cell
types, suggesting that cathepsin L expression is regulated by
nutrient and hormonal signals.
42–44 These findings merit
further studies to clarify the role of hypothalamic cathepsin L
and CUX1 in the mediation of nutritional and hormonal
regulation of hypothalamic Fto expression.
We hypothesized that dysregulation of hypothalamic Fto
expression by nutrients may cause obesity. Hypothalamic
glucose-sensing neurons are fewer in number and show
abnormal responses to glucose in obese or obese-prone
rats.
19,20 The effect of glucose injection on hypothalamic
activity was attenuated in obese humans compared with
non-obese healthy individuals.
21 Furthermore, glucose-in-
duced feeding suppression is absent in obese animals.
18 Both
fasting and glucose treatment did not cause any significant
changes in hypothalamic Fto expression in ob/ob mice in the
present study. Although ob/ob mice showed reduced food
intake in response to CCK, glucose, and 2-DG failed to cause
significant changes in food intake in these mice. These data
clearly indicate that the sensitivity of hypothalamic Fto-
expressing neurons to nutrients, in particular glucose, is
impaired in obesity, resulting in the absence of glucose-
induced anorexia. High-fat diet feeding causes significant
increases in weight gain and hypothalamic Fto mRNA
expression without significant changes in energy intake,
indicating that energy intake per gram of body weight is
actually lower in high-fat diet-fed animals.
11 These findings
suggest that hypothalamic Fto expression is increased to
protect against further weight gain by reducing energy
intake in these animals. It is likely that certain nutritional
factors such as glucose and fat have a stimulatory effect on
Fto expression and hypothalamic Fto-expressing neurons
function towards a counter-regulatory response against
excessive energy intake and the subsequent development
of obesity. Thus, the blunted response of hypothalamic
Fto-expressing neurons to nutrient signals such as glucose
may cause metabolic impairments. It is of interest to
determine whether or not a similar impairment exists in
diet-induced obese animals, which more closely mimic
human obesity.
In conclusion, hypothalamic Fto gene and protein expres-
sion is regulated by metabolic signals, including glucose.
Reduction in circulating glucose levels and/or hypothalamic
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Nutrition and Diabetesglucose availability at least partly mediates fasting-induced
reduction in hypothalamic Fto expression. Obesity is
associated with impairments in glucose-induced hypothala-
mic Fto expression and anorexia. Our findings support the
hypothesis that hypothalamic Fto-expressing neurons have a
role in the regulation of energy homeostasis by monitoring
metabolic states of the body and enhancing Fto expression
and/or activity in the hypothalamus is beneficial in reducing
food intake and obesity.
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